V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009603 | 220003926 | 1.85 | 83.6 | Not known (9) | 2016-04-20 | 2016-04-21 | Methotrexate intrathecal | 2 | N | 220022925 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009604 | 220003927 | 1.58 | 53.6 | Curative (C) | 2013-10-02 | 2013-10-03 | BOSUTINIB | 2 | N | 220023120 | CYTARABINE + MITOXANTRONE |
| 220009605 | 220003928 | 1.76 | 70 | Curative (C) | 2014-09-21 | 2015-07-06 | PONATINIB | N | N | 220023196 | PONATINIB |
| 220009606 | 220003928 | 1.78 | 92.3 | Curative (C) | 2016-11-20 | 2017-01-06 | CISPLATIN + FLUOROURACIL | N | N | 220023196 | TRIPLE INTRATHECAL |
| 220009607 | 220003928 | 1.78 | 95 | Curative (C) | 2017-03-16 | 2017-03-16 | Vemurafenib | 02 | N | 220023196 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220009608 | 220021345 | 1.77 | 75.5 | Curative (C) | 2015-05-06 | 2015-05-06 | CAPECITABINE + CISPLATIN + EPIRUBICIN | N | N | 220023457 | FLUDARABINE + MELPHALAN |
| 220009609 | 220021345 | 1.58 | 67 | Curative (C) | 2016-01-02 | 2016-01-04 | Vemurafenib | 02 | N | 220023457 | IDARUBICIN + MITOXANTRONE + TRETINOIN |
| 220009610 | 220021345 | 1.6 | 48 | Palliative (P) | null | 2019-07-31 | VINCRISTINE | N | N | 220023457 | DOXORUBICIN + IFOSFAMIDE |
| 220009611 | 220021345 | 1.73 | null | Palliative (P) | 2013-04-15 | 2013-04-30 | Alemtuzumab(INTRAVENOUS) | N | null | 220023457 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 220009612 | 220021345 | null | 105.3 | Curative (C) | 2015-11-30 | 2015-12-08 | LENALIDOMIDE | N | N | 220023457 | CISPLATIN |
| 220009613 | 220022172 | 1.56 | 83 | Curative (C) | 2015-10-13 | 2015-10-13 | FLUDARABINE | null | null | 220023638 | CODOX M |
| 220009614 | 220003929 | 1.62 | null | Not known (9) | 2018-07-09 | 2018-07-27 | Ipilimumab | N | N | 220023658 | UKALL2014 |
| 220009615 | 220003930 | null | null | Curative (C) | 2015-12-07 | 2015-12-30 | Fludarabine + Melphalan RIC Allo | N | null | 220023660 | ARSENIC TRIOXIDE + ATRA |
| 220009616 | 220003930 | 1.59 | null | Palliative (P) | 2018-02-21 | 2018-03-12 | Arsenic Trioxide (consolidation) | null | null | 220023660 | CHOP R |
| 220009617 | 220003930 | null | 74.6 | null | 2018-03-15 | 2018-03-18 | ATG + Busulfan + Fludarabine | 02 | N | 220023660 | CYTARABINE INTRATHECAL |
| 220009618 | 220003930 | 1.55 | 88.9 | Disease modification (D) | 2016-09-14 | 2016-09-14 | IDARUBICIN + MITOXANTRONE + Tretinoin | 02 | N | 220023660 | IBRUTINIB |
| 220009619 | 220003930 | null | 63.6 | Curative (C) | 2014-07-17 | 2014-07-17 | LANREOTIDE | N | N | 220023660 | CHOP R |
| 220009620 | 220003930 | 1.71 | null | Curative (C) | 2017-07-23 | 2017-07-23 | CHOP | N | N | 220023660 | LI-1 TRIAL |
| 220009621 | 220003931 | 1.57 | 74.4 | null | 2015-11-08 | 2016-01-06 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE | 02 | N | 220023979 | CYTARABINE INTRATHECAL |
| 220009622 | 220003932 | 2 | 95 | Curative (C) | 2015-09-11 | 2015-09-22 | Mitoxantrone | 2 | null | 220023980 | ARSENIC TRIOXIDE + ATRA |
| 220009623 | 220012100 | null | null | Disease modification (D) | 2013-06-24 | 2013-06-24 | Fludarabine + Melphalan RIC Allo | null | null | 220023986 | QUASAR 2 TRIAL |
| 220009624 | 220012100 | 0 | 53.7 | Not known (9) | 2016-06-11 | 2016-06-11 | Docetaxel + Trastuzumab (Load) | 01 | N | 220023986 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 220009625 | 220003933 | 0 | 67.2 | Palliative (P) | 2016-05-27 | 2016-06-07 | Bortezomib +/- Dexamethasone | 2 | N | 220024069 | MITOXANTRONE |
| 220009626 | 220003933 | 1.59 | null | null | 2015-03-15 | 2015-03-15 | AML LI-1 Trial | N | Y | 220024069 | METHOTREXATE HIGH DOSE |
| 220009627 | 220003933 | 1.5 | 0 | Curative (C) | 2014-08-02 | 2014-08-02 | LENALIDOMIDE | N | Y | 220024069 | CISPLATIN + FLUOROURACIL |
| 220009628 | 220003933 | 1.67 | null | Palliative (P) | 2015-12-01 | 2015-12-24 | Mitox + Tretinoin Spanish Course 3 | 02 | null | 220024069 | IPILIMUMAB |
| 220009629 | 220003934 | null | null | Curative (C) | 2017-01-01 | 2017-01-03 | LENALIDOMIDE | N | N | 220024209 | CYTARABINE INTRATHECAL |
| 220009630 | 220003935 | null | 119.4 | null | null | 2017-11-17 | Sunitinib | Y | N | 220024226 | FLUDARABINE |
| 220009631 | 220003935 | 0 | null | null | 2017-05-03 | 2017-05-06 | Epirubicin | N | N | 220024226 | ECF |
| 220009632 | 220003935 | 1.68 | 67.4 | Curative (C) | 2018-09-06 | 2018-09-06 | Cisplatin + Pemetrexed | 02 | N | 220024226 | CVD |
| 220009633 | 220003935 | 1.65 | 4.3 | Curative (C) | 2018-02-10 | 2018-02-12 | Capecitabine | 2 | N | 220024226 | MITOXANTRONE |
| 220009634 | 220003935 | 1.55 | 63.8 | Palliative (P) | 2015-03-16 | 2015-03-16 | AML LI-1 Trial | N | N | 220024226 | DACARBAZINE |
| 220009635 | 220003936 | 1.66 | 59.7 | Curative (C) | 2018-08-22 | 2018-08-22 | Triple / Double Intrathecal Therapy | N | N | 220024698 | CISPLATIN |
| 220009636 | 220003936 | null | 69.8 | Curative (C) | 2016-02-07 | 2016-02-07 | MELPHALAN | N | N | 220024698 | ARSENIC TRIOXIDE + TRETINOIN |
| 220009637 | 220003936 | 1.63 | null | Palliative (P) | 2019-01-19 | 2019-02-15 | AML LI-1 Trial | 02 | N | 220024698 | CARBO + FLUOROURACIL |
| 220009638 | 220003937 | 1.82 | 68.45 | Palliative (P) | 2016-08-08 | 2016-09-03 | Cisplatin | N | Y | 220025003 | DABRAFENIB + TRAMETINIB |
| 220009639 | 220003937 | 1.5 | null | Palliative (P) | null | 2016-02-16 | Mitoxantrone | null | N | 220025003 | CISPLATIN + FLUOROURACIL |
| 220009640 | 220003937 | 1.61 | 112 | Palliative (P) | 2017-05-07 | 2017-05-08 | CYTARABINE + MITOXANTRONE | 02 | null | 220025003 | DOXORUBICIN + IFOSFAMIDE |
| 220009641 | 220003937 | 1.65 | 87 | Curative (C) | 2016-07-26 | 2016-09-09 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 220025003 | ATG + BUSULFAN + FLUDARABINE |
| 220009642 | 220003937 | null | null | null | null | 2015-09-19 | Cape+Cisplatin+Trastuzumab Load | 99 | null | 220025003 | UKALL XII |
| 220009643 | 220003937 | 1.67 | 83.7 | Palliative (P) | 2016-08-29 | 2016-09-04 | Irinotecan + Modified De Gramont | 2 | N | 220025003 | DACARBAZINE |
| 220009644 | 220003938 | 1.82 | 59.1 | Curative (C) | null | 2017-05-25 | ECarboX | N | N | 220025372 | MITOXANTRONE |
| 220009645 | 220012105 | 1.67 | null | Disease modification (D) | 2016-11-30 | 2016-12-22 | Bortezomib + MELPHALAN | N | N | 220025376 | RUXOLITINIB |
| 220009646 | 220003939 | 1.6 | null | null | 2015-01-20 | 2015-01-20 | FLUOROURACIL | N | N | 220025427 | UKALL2014 |
| 220009647 | 220003939 | 0 | 71 | Curative (C) | 2015-10-15 | 2015-10-15 | LENALIDOMIDE | 02 | N | 220025427 | CYTARABINE + MITOXANTRONE |
| 220009648 | 220003939 | 1.73 | 0 | Not known (9) | 2014-07-01 | 2014-07-06 | Carboplatin + Pemetrexed | 2 | N | 220025427 | THALIDOMIDE |
| 220009649 | 220003939 | 1.67 | 114.5 | null | 2016-03-09 | 2016-04-23 | ETOPOSIDE + IFOSFAMIDE | N | N | 220025427 | ARSENIC TRIOXIDE |
| 220009650 | 220003939 | null | 87.3 | Palliative (P) | null | 2017-01-26 | AXITINIB | N | N | 220025427 | CISPLATIN + PEMETREXED |
| 220009651 | 220003940 | null | null | Curative (C) | null | 2019-07-31 | OCTREOTIDE | null | null | 220026026 | ARSENIC TRIOXIDE |
| 220009652 | 220003941 | 1.75 | 0 | Curative (C) | 2013-06-01 | 2013-07-17 | Cyclophosphamide TBI Allograft | N | N | 220026030 | MITOXANTRONE |